To investigate the clinical diagnostic characteristics of Dagliazine (Dapa) induced hematuria in a diabetic mellitus patient.

The laboratory and imaging test results of a diabetic patient with Dapa-induced hematuria who was hospitalized to the Department of Endocrinology of Jingxian Hospital in the Anhui Province on June 1, 2021 were analyzed. The differential diagnosis of hematuria were done using the evidence-based medical approach, and the potential pathogenesis, course of treatment, and prognosis of hematuria brought on by Dapa were reviewed.

The patient had a history of hypertension and benign prostatic hyperplasia, and he took antihypertensive medications daily. After two months of therapy, the diabetic patient experienced Dapa-associated hematuria, which was macroscopic hematuria. Under a microscope, the red blood cells′ morphology was normal and free of deformity. Following the end of the Dapa therapy, hematuria progressively subsided. The findings of pertinent laboratory and imaging tests ruled out urinary system malignancies in the elderly and did not support the involvement of underlying diseases and cumulative drug influences. The patient′s liver and kidneys were functioning normally and didn′t have any kidney illness, genital organ inflammation, coagulation issues, or any other abnormalities. Hematuria′s incidence could be linked to acute renal injury brought on by Dapa.

Clinicians should carefully choose the Dapa-suitable group, especially the elderly diabetes patients with prostatic hyperplasia. Discontinuing Dapa should be a crucial part of prompt management when hematuria develops in patients during therapy in order to guarantee a positive outcome for the patients.